These multifaceted actions underscore the promising therapeutic potential of Ang-(1-7) in managing fibrosis and COVID-19 patients, with Phase I ensuring safety and Phase II testing efficacy against placebo, including outcomes like oxygen-free days, hospital stay, ICU days, mortality, and ventilation inflammation across diverse conditions, including those linked to Ang II-mediated tissue fibrosis [65]. This evidence concerns the gene ANG and COVID-19.